secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001193125-25-180830
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech Q2 net loss $26.2M; Ph3 Cylembio trial misses PFS endpoint, plans FDA meeting fall 2025
--------------------------------------------------------------------------------

- Phase 3 trial of Cylembio+Keytruda in advanced melanoma showed clinical improvement in PFS but narrowly missed statistical significance.
- Company plans to meet with FDA in fall 2025 to discuss data and potential BLA submission for Cylembio.
- Net loss of $26.2M for Q2 2025 vs $20.7M in Q2 2024; R&D expenses $16.7M, G&A $6.5M.
- Cash and equivalents $28.1M at June 30, 2025; plus €12.5M EIB loan received July 4, funding into Q1 2026.
- Upcoming investor conferences: Morgan Stanley (Sept 9) and H.C. Wainwright (Sept 10) with management presentations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312525180830/0001193125-25-180830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312525180830/d34608d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-180830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer